Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.78 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.53 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL27880305 | 0.89 | ALDH1A1 (0.60) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL28292236 | 0.88 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29396199 | 0.88 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL150011 | 0.88 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL3081560 | 0.88 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL1433 | 0.88 | — | — | |
| Niacin SCHEMBL30844065 | 0.88 | — | — | |
| Niacin SCHEMBL29349574 | 0.88 | — | — | |
| Niacin SCHEMBL811678 | 0.87 | ALDH1A1 (0.75) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL25247085 | 0.86 | ALDH1A1 (0.95) | ALDH1A1APPGAAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| US-20050118257-A1 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | KOS LIFE SCIENCES, INC. | 2005-06-02 | — | — | US | claimed |
| US-20050013790-A1 | External skin care composition | KAO CORPORATION (JP) | 2005-01-20 | — | — | US | claimed |
| US-20040053975-A1 | Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night | KOS LIFE SCIENCES, INC. | 2004-03-18 | — | — | US | claimed |
| US-6469035-B1 | REDUCING THE CAPACITY OF AN EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY ORALLY PRETREATING WITH AN AGENT WHICH INHIBITS OR REDUCES PROSTAGLANDIN PGD2 INDUCED BY NICOTINIC ACID; FDA ORANGE BOOK LISTED PATENT FOR NIACIN AND SIMVASTATIN | KOS LIFE SCIENCES LLC | 2002-10-22 | — | — | US | claimed |
| EP-1017390-A2 | COMBINATIONS OF HMG-COA INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0969837-A1 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR | KOS PHARMACEUTICALS, INC. (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1999006052-A9 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMA INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999006035-A2 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1998039002-A1 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR | KOS PHARMACEUTICALS, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| EP-0643965-A1 | Nicotinic acid compositions for treating hyperlipidemia | KOS PHARMACEUTICALS, INC. (US) | 1995-03-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ALDH1A1 1105/4885APP 1669/4885GAA 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.